Cellectis S.A. (CMVLF)
| Previous close | 3.6700 |
| Open | 3.6700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.6700 - 3.6700 |
| 52-week range | 2.3900 - 14.1800 |
| Volume | |
| Avg. volume | 66 |
| Market cap | 169.86M |
| Beta (5Y monthly) | 2.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9520 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
- GlobeNewswire
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022
IND clearance received from FDA for UCART20x22 for the treatment of Non-Hodgkin LymphomaCellectis unveiled novel immune-evasive universal allogeneic CAR T-cell in Nature Communications; awarded oral presentation at ASGCT in MayMr. Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D. appointed as Directors of Cellectis’ Board of DirectorsCash position1 of $135 million as of June 30, 2022 Conference call scheduled for 8AM ET/2PM CET on August 5, 2022 NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) --
- GlobeNewswire
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies
UCART20x22 is Cellectis’ first allogeneic dual CAR T, targeting CD20 and CD22 simultaneously UCART20x22 is Cellectis’ first product candidate fully designed, developed and manufactured in-house Phase 1/2a clinical trial NatHaLi-01 expected to begin in second half of the year NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and
